

The first Responsome Company to predict Tumor Shrinkage



Founded 2018 by
serial entrepreneurs



Headquarter
Zürich area
Switzerland



European subsidiary
Lörrach
Germany



2.2M CHF seed
round in 2021



1.6M CHF
Technology grant




4 patents filed
2 in preparation



5th of June 2023
ICCS@BIO Boston

BRIDGING THE GAP BETWEEN THE PATIENT AND DRUG DISCOVERY WITH A COMPLETE END-TO-END PHYSIOLOGICAL DRUG TESTING SOLUTION

3DTwin® Screen




Physiological and dynamic drug testing assays

Clinically relevant outcome analysis

Patent applications filed

3DTwin® Profiler




Autonomous testing technology

Tailored for Pharma R&D and clinical implementation

Patent granted in Germany


3DTwin® Flow



AI-powered data pipeline

Automated analysis, data-driven insights

Response




Multi drug-induced -omics

Unraveling multi-drug and patient-specific response

Patent in preparation

PROVIDING PATIENT-SPECIFIC DRUG TESTING THROUGH A CLINICAL EX VIVO DRUG TRIAL NETWORK




* Through pharma partnering

PROMOTE CLINICAL ADOPTION AND CONDUCT STUDIES TO EXPAND PATIENT-SPECIFIC DRUG TESTING CAPABILITIES

2020



2023



Future – clinically validated cancer drug discovery around the world



Proof of clinical concept

- Clinical technology implementation
 - Pediatric cancer
 - Sarcoma
 - NSCLC
 - Immuno-oncology/combinations
- Clinical cross platform validation
- First Pharma feasibility projects

- Clinical validation trials
- Clinical and Pharma partnership expansion
- Broadening cancer indications and applications



Investors for Series A round



Clinical and Pharma collaborations



Technological partnerships

Jens M. Kelm, CEO
jens.kelm@precomb.com

PreComb Therapeutics AG
Garstligweg 8
8634 Hombrechtikon
Switzerland